$4.62-0.02 (-0.43%)
News25/Ratings6
Price$4.62+0.10 (+2.21%)
02:00 PM07:45 PM
News · 26 weeks48-60%
2025-10-262026-04-19
Mix2990d
- Insider14(48%)
- SEC Filings9(31%)
- Offering3(10%)
- Other2(7%)
- Leadership1(3%)
Latest news
25 items- INSIDERSEC Form 4 filed by Frankenius Equity Ab4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- PRTriSalus Life Sciences to Present New Data at the 2026 Society of Interventional Radiology Annual Scientific MeetingTriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced its participation in the Society of Interventional Radiology (SIR) 2026 Annual Scientific Meeting, taking place April 11–15, 2026, in Toronto, Ontario, Canada. TriSalus will showcase new clinical and preclinical data highlighting the capabilities of its Pressure Enabled Drug Delivery™ (PEDD™) platform to enhance therapeutic delivery across multiple disease states. Featured presentations include: April 13, 2026 | 12:10 PM ET
- SECTriSalus Life Sciences Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - TriSalus Life Sciences, Inc. (0001826667) (Filer)
- INSIDERSEC Form 4 filed by Matlin David J4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- INSIDERSEC Form 4 filed by Cox Bryan F.4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- INSIDERSEC Form 4 filed by Devlin Jodi4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- INSIDERSEC Form 4 filed by Marshak Richard4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- INSIDERSEC Form 4 filed by Stevens Jennifer4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- INSIDERSEC Form 4 filed by Szela Mary T4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- PRTriSalus Life Sciences Announces Publication Demonstrating Enhanced Delivery and Immune Activation with Nelitolimod Delivered with Pressure-Enabled Drug Delivery in Liver Tumor ModelsTriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced the publication of preclinical research evaluating Pressure-Enabled Drug Delivery™ (PEDD™) of nelitolimod in liver tumor models in Frontiers in Oncology. The study evaluated the delivery and biologic activity of nelitolimod, an investigational Toll-like receptor 9 (TLR9) agonist, when administered using PEDD, compared with conventional delivery approaches. The research examined therapeutic distribution in a porcine liver tumor mo
- SECSEC Form S-8 filed by TriSalus Life Sciences Inc.S-8 - TriSalus Life Sciences, Inc. (0001826667) (Filer)
- SECSEC Form 10-K filed by TriSalus Life Sciences Inc.10-K - TriSalus Life Sciences, Inc. (0001826667) (Filer)
- SECTriSalus Life Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - TriSalus Life Sciences, Inc. (0001826667) (Filer)
- PRTriSalus Life Sciences Reports Fourth Quarter and Year-End 2025 Results and Reaffirms 2026 Revenue GuidanceReports $13.2 million in Revenue in the Fourth Quarter, $45.2 million for Full-Year of 2025, Representing increases of 60% and 53%, respectively, Versus the Prior Year Periods Reaffirms 2026 Revenue Guidance of $60-62 million Strengthened Balance Sheet with $46 Million Gross Proceeds from Recent Public Offering Hosting Conference Call and Webcast today at 4:30pm ET TriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces financial results for the quarter and year ended December 3
- SECSEC Form 424B5 filed by TriSalus Life Sciences Inc.424B5 - TriSalus Life Sciences, Inc. (0001826667) (Filer)
- INSIDERDirector Gordon Gary B. bought $40,000 worth of shares (9,756 units at $4.10) (SEC Form 4)4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- INSIDERChief Financial Officer Patience David bought $14,994 worth of shares (3,657 units at $4.10), increasing direct ownership by 1% to 268,657 units (SEC Form 4)4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- INSIDERCEO and President Szela Mary T bought $124,997 worth of shares (30,487 units at $4.10), increasing direct ownership by 4% to 773,289 units (SEC Form 4)4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- INSIDERDirector Valle William bought $124,997 worth of shares (30,487 units at $4.10) (SEC Form 4)4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- INSIDERDirector Stansky Michael P bought $1,480,502 worth of shares (361,098 units at $4.10), increasing direct ownership by 45% to 787,132 units (SEC Form 4)4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- SECSEC Form 424B5 filed by TriSalus Life Sciences Inc.424B5 - TriSalus Life Sciences, Inc. (0001826667) (Filer)
- SECSEC Form 8-K filed by TriSalus Life Sciences Inc.8-K - TriSalus Life Sciences, Inc. (0001826667) (Filer)
- PRTriSalus Life Sciences Announces Pricing of $40.0 Million Public OfferingTriSalus Life Sciences, Inc. (NASDAQ:TLSI) ("TriSalus" or the "Company"), an oncology focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies to improve outcomes for patients with solid tumors, today announced it has priced its previously announced underwritten public offering of 9,756,100 shares of its common stock at a public offering price of $4.10 per share. All of the shares in the offering are being sold by TriSalus. In addition, TriSalus has granted the underwriter a 30-day option to purchase up to 1,463,415 shares of common stock, which equals 15% of the total number of shares of common stock sold in the offering, at the pub
- SECSEC Form 424B5 filed by TriSalus Life Sciences Inc.424B5 - TriSalus Life Sciences, Inc. (0001826667) (Filer)
- PRTriSalus Life Sciences Proposes Public OfferingTriSalus Life Sciences, Inc. (NASDAQ:TLSI) ("TriSalus" or the "Company"), an oncology focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies to improve outcomes for patients with solid tumors, today announced that it intends to offer to sell shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering are to be sold by TriSalus. In addition, TriSalus intends to grant the underwriters a 30-day option to purchase up to 15% of the total number of shares of common stock sold in the offering, on the same terms and conditions. The offering is subject to market and other conditions, and there